Immune gene expression profile of Penaeus monodon in response to marine yeast glucan application and white spot syndrome virus challenge

2015 ◽  
Vol 43 (2) ◽  
pp. 346-356 ◽  
Author(s):  
Wilsy Wilson ◽  
Douglas Lowman ◽  
Swapna P. Antony ◽  
Jayesh Puthumana ◽  
I.S. Bright Singh ◽  
...  
Keyword(s):  
Gene Expression ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
White Spot Syndrome Virus ◽  
Penaeus Monodon ◽  
White Spot ◽  
Immune Gene ◽  
Marine Yeast ◽  
Virus Challenge ◽  
Immune Gene Expression

Gene Networks and Canonical Pathways Analysis in Classical Hodgkin Lymphoma Patients

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5298-5298
Author(s):  
Priscilla Brito Silva ◽  
Juliana Monte Real ◽  
Otavio C. G. Baiocchi ◽  
Gustavo Henrique Esteves ◽  
Joao Garibaldi Junior ◽  
...  
Keyword(s):  
Gene Expression ◽  
Hodgkin Lymphoma ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Gene Interaction ◽  
Immune Gene ◽  
Immune Gene Expression ◽  
Gene Interaction Networks ◽  
Canonical Pathways ◽  
Nfkb Pathway

Abstract Introduction: Molecular alterations involved in development of classical Hodgkin lymphoma (cHL) are only partially known. Genetic alterations in NFkB pathway and the imbalance of T regulatory (Treg) and TH17 lymphocytes has been recognized as critical pathogenetic mechanism involved in immune scape and blockade of apoptosis in Reed-Sternberg cells. Emerging evidences suggests that NFkB activation can promote lymphocyte proliferation and survival, and therapeutic inhibition of the NFkB pathway have been proposed. Recently, our group showed an increase of circulating Treg cells in patients with cHL at diagnosis, however, after therapy, elevated levels of circulating TH17 cells was observed. Increased frequencies of Treg lymphocytes in the tumor microenvironment and peripheral blood have been proposed as one of the mechanisms for this anergic state. TH17 exhibit effector functions in immune system and tumor-infiltrating TH17 cells are associated with better prognosis in human. Objectives: In this study we aimed to evaluate the immune gene expression profile in whole blood of cHL patients at diagnosis and after treatment, and evaluate pathways and gene interaction networks. Methods: This is an open multicenter study and, so far, we included 51 patients consecutively from February 2011 to November 2015. Twenty consecutively diagnosed cHL patients, with whole blood RNA extracted at diagnosis and after treatment, were recruited for this study and prospectively evaluated. All patients were HIV negative and received ABVD chemotherapy protocol and radiotherapy if necessary. The general expression of 96 messengers RNAs present in the peripheral blood and involved in immune response was performed by a customized quantitative real-time PCR array (TaqMan¨ Low Density Array). The data was normalized with B2M mRNAs levels and relative gene expression was calculated by the 2^DDCt method, considering Wilcoxon test and Benjamini-Hochberg adjustment to correct p-values. The differentially expressed genes were used to conduct functional/pathway enrichment analysis and construct gene interaction networks. Functional annotation networks were generated using Ingenuity Pathway Analysis (IPA; Ingenuity Systems) software. Results: From the 20 patients included for this study, 12 (60%) were male, 5 (31%) had Epstein Barr virus related cHL, 18 (90%) patients presented with B symptoms, 19 (95%) patients had advanced diseases at diagnosis (stage IIBX, III and IV) and 10% of patients relapsed. We considered paired samples from 15 patients before and after treatment. At diagnosis we observed that cHL patients presented higher expression of CD274 (2 fold, p=0.018), CD28 (1.5 fold, p=0.041), CTLA-4(1.5 fold, p=0.004), FAS (1.4 fold, p=0.041), ICOS (2.1 fold, p=0.015) and IL-10 (2.7 fold, p=0.002), and decreased expression of CCL2 (-2.7 fold, p=0.026), CCL5 (-1.6 fold, p=0.012), CD40 (-1.9 fold, p=0.003), CSF2 (-1.9 fold, p=0.012). We found no association between clinical and epidemiological characteristics with immune gene expression profile. We have found that after treatment, patients displayed a specific gene expression profile related to the top 5 canonical pathways summarized in following figure: We also built a biological network to investigate the connection between the differentially expressed genes and to predict the status (activation/inhibition) of the other connected genes (nodes). The in silico analysis revealed that NFkB, a node which its signaling activation is predicted to be activated before treatment and inhibited after (following figures). The network also showed different central node molecules (molecules connected with multiple other nodes from the network), that are indirectly related to Hodgkin lymphoma and should be further investigated as potential drugable targets. Conclusions: In this study, we showed that, at diagnosis, cHL patients presented an inflammatory gene expression profile in blood that changes after treatment to an effector/immunological one. NFkB is predicted to be activated before treatment and inhibited after ABVD chemotherapy and radiotherapy. This kind of system biology approach helped us to understand that cHL associated immunosuppression and the immune reconstitution after treatment maybe the key to develop new prognostic factors and treatment strategies as well as identify drugable targets. Figure 1 Figure 1. Figure 2 Figure 2. Figure 3 Figure 3. Disclosures No relevant conflicts of interest to declare.

Impact of Treatment on IL-10, CTLA-4 and PD-L1 Gene Expression in Patients with Classical Hodgkin Lymphoma

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5290-5290
Author(s):  
Priscilla Brito Silva ◽  
Juliana Monte Real ◽  
Ludmila Rodrigues Pinto Ferreira ◽  
Gustavo Henrique Esteves ◽  
Joao Garibaldi Junior ◽  
...  
Keyword(s):  
Gene Expression ◽  
Immune Response ◽  
Hodgkin Lymphoma ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Peripheral Blood ◽  
Immune Gene ◽  
Classical Hodgkin Lymphoma ◽  
Immune Gene Expression ◽  
Abvd Chemotherapy

Abstract Introduction: Interleukin (IL)-10 is an anti-inflammatory cytokine with potent inhibitory effects in immune response. Higher expression of IL-10 has also been detected in classical Hodgkin lymphoma (cHL), and it has been suggested that the cytokine is involved in the pathogenesis of these tumors. CTLA-4 has long been recognized as regulatory function, potentially decreasing antitumor immune response. Augmentation of the immune response via blockade of CTLA-4 has shown an improvement in survival for patients with metastatic melanoma, Overexpression of PD-L1 on Reed-Sternberg cells is related with downregulation of effector T cell function and represents a potent mechanism of tumor evasion. PD-L1 inhibitors have shown excellent results in refractory cHL patients. Objectives: The aim of the study was to evaluate the immune gene expression profile in peripheral blood of cHL patients at diagnosis and post-treatment and correlate these findings with clinical and epidemiological aspects. Patient and Methods: This is an open multicenter study and, so far, we included 51 patients consecutively from February 2011 to November 2015. Twenty consecutively diagnosed cHL patients, with whole blood RNA extracted at diagnosis and after treatment, were recruited for this study and prospectively evaluated. The general expression of 96 messengers RNAs present in the peripheral blood and involved in immune response was performed by a customized quantitative real-time PCR array (TaqMan¨Low Density Array). The data was normalized with B2M mRNAs levels and relative gene expression was calculated by the 2^DDCt method, considering Wilcoxon test and Benjamini-Hochberg adjustment to correct p-values. In this study, only cHL patients whose histology could be confirmed were studied. All patients were HIV negative and received ABVD chemotherapy protocol and radiotherapy if necessary. Results: From the 20 patients included in this study, 12 (60%) were male, 5 (31%) had Epstein Barr virus related cHL, 18 (90%) patients presented with B symptoms, 19 (95%) patients had advanced disease at diagnosis (stage IIBX, III and IV). Results of immune gene expression profile in paired samples from 15 patients before (pre) treatment and after (post) treatment are summarized in the following table: We observed higher expression of CD274 (PD-L1), CTLA-4 and IL-10 mRNAs in patients at diagnosis compared to expression after treatment. We found no association between relapse and immune gene expression or epidemiological and clinical characteristics. Conclusions: In this study we showed that IL-10, CD274 (PD-L1) and CTLA4 are downregulated after therapy, which suggests a mechanism for tumor immune evasion that was reverted by ABVD chemotherapy and radiotherapy. Understanding cHL associated immunosuppression and the immune reconstitution after treatment maybe the key to develop new prognostic factors and treatment strategies. Table Table. Disclosures No relevant conflicts of interest to declare.

scholarly journals Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence

Liver Cancer ◽  
2018 ◽  
Vol 7 (3) ◽  
pp. 277-294 ◽  
Author(s):  
Chiara Carone ◽  
Andrea Olivani ◽  
Raffaele Dalla Valle ◽  
Roberta Manuguerra ◽  
Enrico Maria Silini ◽  
...  
Keyword(s):  
Gene Expression ◽  
Hepatocellular Carcinoma ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Tumor Recurrence ◽  
Surrounding Tissue ◽  
Immune Gene ◽  
Immune Gene Expression

Gene Expression Profile in Patients with Classical Hodgkin Lymphoma in Brazil: Results from a Pilot Study

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5294-5294
Author(s):  
Priscilla Brito Silva ◽  
Juliana Monte Real ◽  
Ludmila Rodrigues Pinto Ferreira ◽  
Gustavo Henrique Esteves ◽  
Joao Garibaldi Junior ◽  
...  
Keyword(s):  
Gene Expression ◽  
Immune Response ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Immune Gene ◽  
Healthy Controls ◽  
Classical Hodgkin Lymphoma ◽  
Immune Gene Expression ◽  
Effective Immune Response ◽  
The Impact

Abstract Introduction: Although immunosuppression has long been recognized in classical Hodgkin lymphoma (cHL), the underlying basis for this lack of an effective immune response against tumor remains unclear. Recently, our group showed increased frequencies levels of pro and anti-inflammatory cytokines, such as interleukins IL-6, IL-10, TNF-alpha and sCD25 in cHL patients and the impact of treatment on these cytokines. These cytokines participate in the Hodgkin and Reed-Sternberg (HRS) cells survival and immunological escape. Objectives: In this study we aimed to evaluate the immune gene expression profile in cHL patients at diagnosis and the impact of treatment on this profile. Patient and Methods: This is an open multicenter study and, so far, we included 51 patients consecutively from February 2011 to November 2015. Twenty consecutively diagnosed cHL patients, with whole blood RNA extracted at diagnosis and after treatment, were recruited for this study and prospectively evaluated. The general expression of 96 messengers RNAs present in the peripheral blood and involved in immune response was performed by a customized quantitative real-time PCR array (TaqMan¨Low Density Array). We also included 7 healthy controls. The data was normalized with B2M mRNAs levels and relative gene expression was calculated by the 2^DDCt method, considering Wilcoxon test and Benjamini-Hochberg adjustment to correct p-values. In this study, only cHL patients whose histology could be confirmed were studied. All patients were HIV negative and received ABVD chemotherapy protocol and radiotherapy if necessary. Results: From the 20 patients included for this study, 12 (60%) were male, 5 (31%) had Epstein Barr virus related cHL, 18 (90%) patients presented with B symptoms, 19 (95%) patients had advanced diseases at diagnosis (stage IIBX, III and IV) and 10% of patients relapsed. Results of immune gene expression profile in patients before (pre) treatment, after (post) treatment and healthy subjects (controls) are summarized in the following table: We observed that 4 mRNAs were altered in cHL patients before therapy (IL-10, CCL2, CD40 and HLA-DRA). After treatment, gene expression profile was similar to healthy controls. When we considered paired samples from 15 patients, 10 mRNAs were differently expressed after therapy, although the adjusted p value showed no different expression. We found no association between clinical and epidemiological characteristics with immune gene expression profile. Conclusions: In this study we showed that, in comparison with healthy donors, cHL patients presented higher expression of inflammatory genes in peripheral blood at diagnosis. After treatment, gene expression profile was comparable to healthy controls. Furthermore, treatment seems to restore a more effective immune response; particularly, IL-10, CD274 (PD-L1) and CTLA4 which were downregulated after therapy. Understanding cHL associated immunosuppression and the immune reconstitution after treatment maybe the key to develop new prognostic factors and treatment strategies. Table Table. Disclosures No relevant conflicts of interest to declare.

scholarly journals Expression Profile of Penaeus monodon Ubiquitin Conjugating Enzyme (PmUbc) at Protein Level in White spot syndrome virus Challenged Shrimp

2013 ◽  
Vol 24 (1) ◽  
pp. 48-53 ◽  
Author(s):  
Jeena Keezhedath ◽  
Pani Prasad Kurcheti ◽  
Mujahid Khan Pathan ◽  
Gireesh P. Babu ◽  
Gayatri Tripathi ◽  
...  
Keyword(s):  
Expression Profile ◽  
Protein Level ◽  
White Spot Syndrome Virus ◽  
Penaeus Monodon ◽  
White Spot ◽  
Ubiquitin Conjugating Enzyme ◽  
White Spot Syndrome ◽  
Conjugating Enzyme

Expression profile of bio-defense genes in Penaeus monodon gills in response to formalin inactivated white spot syndrome virus vaccine

2015 ◽  
Vol 117 ◽  
pp. 60-68 ◽  
Author(s):  
N.S. Sudheer ◽  
Gigi Poulose ◽  
Ancy Thomas ◽  
Kiron Viswanath ◽  
Amod Kulkarni ◽  
...  
Keyword(s):  
Expression Profile ◽  
Virus Vaccine ◽  
White Spot Syndrome Virus ◽  
Penaeus Monodon ◽  
White Spot ◽  
Defense Genes ◽  
White Spot Syndrome
Sign in / Sign up

Export Citation Format

Share Document